Canadian Consortium Extends Funding for Drug Research

Jul 01, 2014
By BioPharm International Editors

Ontario Centres of Excellence (OCE) and the Ontario Brain Institute (OBI) have announced a partnership with CQDM to bring an additional $3 million to two programs dedicated to breakthrough technologies to accelerate drug discovery and development.

With an investment of $500,000, OCE is joining CQDM in launching the 2014 edition of CQDM’s Explore Program to fund the Ontario arm. The initiative fosters innovative and unconventional game-changing biopharmaceutical research. This is the first time this program will be open to researchers in Ontario as well as in Quebec, thanks to the partnership with OCE.

With a commitment of up to $2.5 million, OBI embarks with CQDM and Brain Canada on the new national initiative in neuroscience Focus on Brain. OBI¹s contribution thus brings to $12.5 million the total funding available to researchers in academia as well as SMEs across Canada, for the development of breakthrough technologies to accelerate the discovery of drugs for disorders of the brain and nervous system. OBI’s funding will be dedicated to Ontario-based entities.

CQDM is a pharma-based consortium active in pre-competitive research whose mission is to fund the development of innovative tools and technologies to accelerate drug discovery and development.

Source: CDQM